U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C5H8NO3S.Na
Molecular Weight 185.177
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIOPRONIN SODIUM

SMILES

[Na+].CC(S)C(=O)NCC([O-])=O

InChI

InChIKey=BKHJWWRUVITKEE-UHFFFAOYSA-M
InChI=1S/C5H9NO3S.Na/c1-3(10)5(9)6-2-4(7)8;/h3,10H,2H2,1H3,(H,6,9)(H,7,8);/q;+1/p-1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB06823 https://en.wikipedia.org/wiki/Tiopronin

Tiopronin is a prescription thiol drug used primarily in the treatment of severe homozygous cystinuria. Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation. Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation. It is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization. As cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects. Tiopronin is dosed on an individual basis using close monitoring of urinary cystine concentrations and urinary output. Tiopronin is a chelating agent. It works by removing extra cystine (the cause of kidney stones) from the urine, which keeps the kidney stones from forming. It works by reacting with urinary cysteine to form a more soluble, disulfide linked, tiopronin-cysteine complex.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
THIOLA

Approved Use

Tiopronin

Launch Date

1988
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.6 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIOPRONIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
29 μg × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIOPRONIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
18.7 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIOPRONIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 g 3 times / day multiple, oral
Highest studied dose
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43-74
n = 9
Health Status: unhealthy
Condition: aneurysmal subarachnoid hemorrhage
Age Group: 43-74
Sex: M+F
Population Size: 9
Sources:
1 g 1 times / day multiple, oral
Highest studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 56.7
n = 28
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 56.7
Sex: M+F
Population Size: 28
Sources:
Other AEs: Proteinuria, Stomatitis...
Other AEs:
Proteinuria (4 patients)
Stomatitis (3 patients)
Itching (2 patients)
Discomfort epigastric (1 patient)
Sources:
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Other AEs: Anemia, Nausea...
Other AEs:
Anemia (6%)
Nausea (12%)
Emesis
Diarrhea (6%)
Abdominal pain (6%)
Oral ulceration (18%)
Fever
Weakness (12%)
Fatigue
Edema peripheral (6%)
Chest pain (6%)
Anorexia
Arthralgia (12%)
Proteinuria (6%)
Impotence (6%)
Cough (6%)
Rash (12%)
Ecchymosis
Pruritus (6%)
Urticaria
Skin wrinkling (6%)
Sources:
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Other AEs: Anemia, Nausea...
Other AEs:
Anemia (2%)
Nausea (25%)
Emesis (10%)
Diarrhea (18%)
Abdominal pain
Oral ulceration (12%)
Fever (8%)
Weakness (4%)
Fatigue (14%)
Edema peripheral (6%)
Chest pain
Anorexia (8%)
Arthralgia
Proteinuria (10%)
Impotence
Cough
Rash (14%)
Ecchymosis (6%)
Pruritus (4%)
Urticaria (8%)
Skin wrinkling (6%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Discomfort epigastric 1 patient
1 g 1 times / day multiple, oral
Highest studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 56.7
n = 28
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 56.7
Sex: M+F
Population Size: 28
Sources:
Itching 2 patients
1 g 1 times / day multiple, oral
Highest studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 56.7
n = 28
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 56.7
Sex: M+F
Population Size: 28
Sources:
Stomatitis 3 patients
1 g 1 times / day multiple, oral
Highest studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 56.7
n = 28
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 56.7
Sex: M+F
Population Size: 28
Sources:
Proteinuria 4 patients
1 g 1 times / day multiple, oral
Highest studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 56.7
n = 28
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 56.7
Sex: M+F
Population Size: 28
Sources:
Anorexia
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Ecchymosis
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Emesis
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Fatigue
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Fever
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Urticaria
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Arthralgia 12%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Nausea 12%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Rash 12%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Weakness 12%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Oral ulceration 18%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Abdominal pain 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Anemia 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Chest pain 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Cough 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Diarrhea 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Edema peripheral 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Impotence 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Proteinuria 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Pruritus 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Skin wrinkling 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 17
Health Status: unhealthy
Condition: cystinuria
Population Size: 17
Sources:
Abdominal pain
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Arthralgia
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Chest pain
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Cough
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Impotence
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Emesis 10%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Proteinuria 10%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Oral ulceration 12%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Fatigue 14%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Rash 14%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Diarrhea 18%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Anemia 2%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Nausea 25%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Pruritus 4%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Weakness 4%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Ecchymosis 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Edema peripheral 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Skin wrinkling 6%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Anorexia 8%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Fever 8%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Urticaria 8%
0.267 g 3 times / day multiple, oral
Recommended
Dose: 0.267 g, 3 times / day
Route: oral
Route: multiple
Dose: 0.267 g, 3 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: cystinuria
Population Size: 49
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.
2000 Jul-Aug
Brief murine myocardial I/R induces chemokines in a TNF-alpha-independent manner: role of oxygen radicals.
2001 Dec
Reactive oxygen species in mechanical stress-induced cardiac hypertrophy.
2001 Dec 14
The cytotoxic effects of diesel exhaust particles on human pulmonary artery endothelial cells in vitro: role of active oxygen species.
2001 Mar 1
Attenuation of the acute adriamycin-induced cardiac and hepatic oxidative toxicity by N-(2-mercaptopropionyl) glycine in rats.
2001 Nov
A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria.
2001 Oct
15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors.
2001 Oct 12
Effect of treatment on ventricular function and troponin I proteolysis in reperfused myocardium.
2002 Apr
Isoflurane preconditions myocardium against infarction via release of free radicals.
2002 Apr
The relative order of mK(ATP) channels, free radicals and p38 MAPK in preconditioning's protective pathway in rat heart.
2002 Aug 15
Acetylcholine leads to free radical production dependent on K(ATP) channels, G(i) proteins, phosphatidylinositol 3-kinase and tyrosine kinase.
2002 Aug 15
Oxidant species trigger late preconditioning against myocardial stunning in conscious rabbits.
2002 Jan
Yellow nail syndrome associated with thiol compound therapy for rheumatoid arthritis. Two case reports.
2002 Jun
Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart.
2002 May
The new MATH: homology suggests shared binding surfaces in meprin tetramers and TRAF trimers.
2002 Oct 23
Mitochondrial adenosine triphosphate-regulated potassium channel opening acts as a trigger for isoflurane-induced preconditioning by generating reactive oxygen species.
2003 Apr
Urinary excretion of total cystine and the dibasic amino acids arginine, lysine and ornithine in relation to genetic findings in patients with cystinuria treated with sulfhydryl compounds.
2003 Dec
Au nanoparticle-enhanced surface plasmon resonance sensing of biocatalytic transformations.
2003 Dec 15
Effects of N-(2-mercaptopropionyl)-glycine on mitochondrial function in ischemic-reperfused heart.
2003 Feb
Modifications of myosin-regulatory light chain correlate with function of stunned myocardium.
2003 Jul
Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors.
2003 Jul
Protective effect of N2-mercaptopropionylglycine on rats and dogs liver during ischemia/reperfusion process.
2003 Jul-Sep
[Cystinuria - Cystine Stones: Recommendations for Diagnosis, Therapy and Follow-up].
2003 Mar
The cardioprotective effect of sevoflurane depends on protein kinase C activation, opening of mitochondrial K(+)(ATP) channels, and the production of reactive oxygen species.
2003 Nov
Polyherbal extract of septilin protects mice against whole body lethal dose of gamma radiation.
2004 Aug
Yellow nail syndrome in rheumatoid arthritis: a drug-induced disease?
2004 Aug
Delayed cardioprotection is mediated via a non-peptide delta opioid agonist, SNC-121, independent of opioid receptor stimulation.
2004 Jan
Oligonucleotide-displaced organic monolayer-protected silver nanoparticles and enhanced luminescence of their salted aggregates.
2004 Jul 1
Reactive oxygen species precede protein kinase C-delta activation independent of adenosine triphosphate-sensitive mitochondrial channel opening in sevoflurane-induced cardioprotection.
2004 Mar
Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts.
2004 Mar
The effects of ionizing radiation on DNA: the role of thiols as radioprotectors.
2004 Mar 26
Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity.
2004 May
Effect of change in cellular GSH levels on mitochondrial damage and cell viability loss due to mitomycin c in small cell lung cancer cells.
2004 Nov 1
HPLC study of tyrosinase inhibition by thiopronine.
2004 Sep
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Urinary cystine should be measured at 1 month after THIOLA treatment, and every 3 months thereafter. THIOLA dosage should be readjusted depending on the urinary cystine value.
THIOLA (Tiopronin) may be begun at a dosage of 800 mg/day in adult patients with cystine stones. In a multiclinic trial, average dose of THIOLA was about 1000 mg/day. In children, initial dosage may be based on 15 mg/kg/day. Whenever possible, THIOLA should be given in divided doses 3 times/day at least one hour before or 2 hours after meals.
Route of Administration: Oral
In Vitro Use Guide
Tiopronin (2 mM) completely prevents the Cisplatin-induced increase in enzyme leakage and substantially blocks the decrease of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction caused by Cisplatin. Tiopronin also significantly protects the renal slices from cisplatin-induced toxic effects. Tiopronin protects against cisplatin-induced nephrotoxicity by acting as an alternative target for Cisplatin both intra- and extracellularly and thus protects against cisplatin-induced depletion of glutathione in the kidney cell
Name Type Language
TIOPRONIN SODIUM
WHO-DD  
Common Name English
TIOPRONIN SODIUM SALT
Common Name English
SODIUM 2-MERCAPTOPROPIONYLGLYCINE
Systematic Name English
GLYCINE, N-(2-MERCAPTO-1-OXOPROPYL)-, SODIUM SALT (1:1)
Common Name English
(±)-TIOPRONIN SODIUM
Common Name English
TIOPRONIN SODIUM, (±)-
Common Name English
N-(2-MERCAPTO-1-OXOPROPYL)GLYCINE MONOSODIUM SALT
Common Name English
Tiopronin sodium [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
23672295
Created by admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
PRIMARY
CAS
2015-25-0
Created by admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
PRIMARY
EVMPD
SUB04881MIG
Created by admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
PRIMARY
FDA UNII
33F0GJ6GBH
Created by admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
PRIMARY
EPA CompTox
DTXSID20942195
Created by admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
PRIMARY
SMS_ID
100000084629
Created by admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
PRIMARY